GNFT - 89bio Files Initial Registration Statement For U.S. IPO
Quick Take
89bio (ETNB) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement.
The firm is focused on developing and commercializing treatments for liver and cardio-metabolic diseases.
ETNB plans to start Phase 2 trials in 2020 and faces significant competition in the NASH treatment market.
Company & Technology
San Francisco, California-based 89bio was founded in 2018 to develop and commercialize therapeutics for the treatment of liver and cardio-metabolic diseases such as NASH.
Management is headed by CEO and Director Rohan Palekar,